news, journals and articles from all over the world.
A Phase 2 clinical trial has started of DS-1211 in individuals with Pseudoxanthoma Elasticum (PXE), a rare multisystem genetic disease that causes calcium deposits in soft tissue resulting in considerable morbidity. DS-1211 is a potential first-in-class small molecule developed through a research collaboration between Daiichi Sankyo and Sanford Burnham Prebys.
For the third time, Sanford Burnham Prebys has been selected by the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., supporting the NCI Experimental Therapeutics (NExT) Program as a Center for the Chemical Biology Consortium (CBC).
Two drugs — one brand new — reverse pancreatic cell changes that presage one of the hardest cancers to treat. Tested in cells, the drugs would be a promising early cancer treatment if they work in clinical trials.
New center will focus on enabling high-performance molecular dynamics simulations via oneAPI—an open, standards-based, cross-architecture programming model for CPUs and accelerators for faster application performance, more productivity and greater innovation.
The September issue of SLAS Discovery is now available open access on ScienceDirect.
Researchers at the University of Illinois Chicago are working with the National Institutes of Health and University of Minnesota to establish a center for antiviral drug development for pandemic-level viruses, including Ebola and SARS-CoV-2.
Today, Gilson announced a new UV-VIS detector to its VERITY® line of purification systems. The VERITY® 1741 UV-VIS Detector is specifically designed with the needs of semi-preparative and preparative HPLC customers in mind.
Texas Biomedical Research Institute Professor Luis Martinez-Sobrido, PhD, an expert in virology, vaccines and antiviral research, has been recruited to collaborate with three of the nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern announced by NIH this spring.
The July issue of SLAS Discovery is now available Open Access on ScienceDirect.
Two of the most common genetic changes that cause cells to become cancerous, which were previously thought to be separate and regulated by different cellular signals, are working in concert, according to new research from the University of Wisconsin–Madison. To date, researchers have focused on finding drugs that block one or the other to treat cancer.
Current advances include new biomarkers to predict chimeric antigen receptor (CAR) T cell therapy outcomes and neurotoxicities, novel treatment targets for pre-cancerous pancreatic lesions and T-cell acute lymphoblastic leukemia, a new approach to improve immunotherapy responses in cold tumors, a profile of synthetic lethal targets for cancers with tumor suppressor loss, and promising clinical data for acute myeloid leukemia and cancers of unknown primary.
The National Institutes of the Health (NIH) has awarded researchers at the Icahn School of Medicine at Mount Sinai a four-year grant to study the role of the human microbiome in rheumatoid arthritis, systemic lupus, and other autoimmune diseases. The grant is part of the NIH’s Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) program, which is designed to speed the discovery of new treatments and diagnostics. It will support the Microbiome Technology and Analytic Center Hub (Micro-TEACH), a multidisciplinary team of researchers at Icahn Mount Sinai and NYU Langone Health.
COVID-19, MIS-C and KD all share a similar underlying mechanism involving the over-activation of particular inflammatory pathways, UC San Diego study shows. Findings support novel drug targets for MIS-C.
A cross-college collaboration at The University of Alabama in Huntsville (UAH) has developed a self-learning artificial intelligence (AI) platform that uses big data analytics to discover how new pharmaceutical drugs and various molecules work inside living cells.
Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2022 class of Harrington Scholar-Innovators. The scholar awards will support a diverse set of drug discovery projects including new treatments for pulmonary diseases, COVID-19, multiple cancers, corneal disease, hepatitis, and acquired spinal cord injuries.
Demand for new kinds of antibiotics is surging, as drug-resistant and emerging infections are becoming an increasingly serious global health threat. Researchers are racing to reexamine certain microbes that serve as one of our most successful sources of therapeutics: the…
Cardamonin — a natural compound found in the spice cardamom and other plants — could have therapeutic potential for triple-negative breast cancer, according to a new study using human cancer cells. The findings also show that the compound targets a gene that helps cancer cells elude the immune system.
Four San Antonio research institutes are collaborating to develop treatments against Nipah virus before it spreads. The World Health Organization has named Nipah virus a priority disease in need of urgent research and development because no approved vaccines or treatments exist.
The Society for Laboratory Automation and Screening (SLAS) will host its popular Innovation AveNEW for startups at Drug Discovery 2021 in Liverpool, UK on October 19-20. Presented by The European Laboratory Research & Innovation Group (ELRIG), Drug Discovery 2021 returns to an in-person meeting format with a mission to engage quality discussions on key issues and future directions in preclinical drug discovery.
University of Utah Health scientists have identified a molecule that slows cells’ production of alpha-synuclein, a protein that forms toxic aggregates in the brains of people with Parkinson’s disease. Its discovery points toward a new strategy for treating the disease and potentially stopping its progression.
The September edition of SLAS Discovery is a Special Collection featuring the cover article, “Applications of Biophysics in Early Drug Discovery” by Geoffrey A. Holdgate (AstraZeneca, Macclesfield, UK) and Christian Bergsdorf, Ph.D. (Novartis Institutes for Biomedical Research, Basel, Switzerland).
Stem cell models derived from people with specific genomic variation recapitulate aspects of their autism spectrum disorder, providing a valuable model to study the condition and look for therapeutic interventions.
An untapped trove of desirable drug-like molecules is hidden in the genomes of Streptomyces bacteria — the same bacteria responsible for the first bacterial antibiotics to treat tuberculosis back in the 1940s. Isolating them, however, has proved challenging. Now, biologists at Washington University in St. Louis are using comparative metabologenomics to try to uncover what may be “silencing” Streptomyces and preventing it from producing desirable compounds encoded by its genes.
The August edition of SLAS Discovery is a Special Collection featuring the cover article, “Approaches for Prioritizing High-Quality Chemical Matter in Chemical Probe and Drug Discovery” by Jayme L. Dahlin, M.D., Ph.D. (Brigham and Women’s Hospital, Boston, MA, USA).
Researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval.
Scientists at Oak Ridge National Laboratory and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in medicine, industry and agriculture.
UC San Diego studies using human cell lines and tumors grown in mice provide early evidence that inhibiting RNA-binding proteins, a previously overlooked family of molecules, might provide a new approach for treating some cancers.
The July edition of SLAS Discovery is a Special Edition featuring the cover article, “Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry” by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).
Activity of the polycomb repressive complex 1 is essential for the development and maintenance of leukemic cells; disrupting it presents a new potential therapeutic approach.
Scientists have published the first detailed atomic-level model of the SARS-CoV-2 “envelope” protein bound to a human protein essential for maintaining the lining of the lungs. The findings may speed the search for drugs to block the most severe effects of COVID-19.
The June edition of SLAS Discovery features the cover article, “A Perspective on Synthetic Biology in Drug Discovery and Development—Current Impact and Future Opportunities” by Florian David, Ph.D. (Chalmers University of Technology, Gothenburg, Sweden), Andrew M. Davis, Ph.D. (AstraZeneca, Cambridge, England, UK). Michael Gossing, Ph.D., Martin A. Hayes, Ph.D., and Elvira Romero, Ph.D., and Louis H. Scott, Ph.D. (AstraZeneca, Gothenburg, Sweden), and Mark J. Wigglesworth, Ph.D. (AstraZeneca, London, England, UK).
Researchers have developed first-in-class small-molecule inhibitors against a key leukemia protein, ASH1L.
New Brunswick, N.J. (March 3, 2021) – The 3D structures of more than 1,000 SARS-CoV-2 coronavirus proteins are freely available from the RCSB Protein Data Bank headquartered at Rutgers University–New Brunswick. The data bank reached the milestone this week, with 1,018 proteins as…
As large multi-cancer datasets become more important for predicting who may benefit from cancer drugs, a new model better accounts for potentially overlooked variation.
A lab on UNLV’s campus has been a hub of activity in recent years, playing a significant role in a new realm of drug discovery — one that could potentially provide a solution for patients who have run out of options.
ORNL story tips: Modeling COVID, permafrost lost and taking the heat
The February edition of SLAS Technology is a special collection of articles focused on “Artificial Intelligence in Process Automation” by Guest Editor Cenk Ündey, Ph.D. (Amgen, Thousand Oaks, CA, USA).
The February edition of SLAS Discovery is a Special Issue on Hit Discovery Methodologies edited by Mark Wigglesworth, Ph.D., (Medicines Discovery Catapult, Stockport, EN, UK) and Peter Hodder, Ph.D. (Amgen, Thousand Oaks, CA, USA).
Two students working under the mentorship of Desigan Kumaran, a structural biologist at the U.S. Department of Energy’s Brookhaven National Laboratory, have helped to identify molecules that could potentially lead to new antiviral drugs for treating COVID-19. Though the students conducted their fall 2020 internships remotely, the potential of their work is firmly planted in the real world and could have lasting impact.
The January edition of SLAS Discovery features the cover article, “Cryo-EM: The Resolution Revolution and Drug Discovery” by Taiana Maia de Oliveira, Ph.D., Lotte van Beek, Ph.D., Fiona Shilliday, Ph.D., Judit E. Debreczeni, Ph.D., and Chris Phillips, Ph.D., from AstraZeneca.
The PhRMA Foundation announced the first recipients of its new funding awards in Drug Discovery and Drug Delivery, designed to support the innovative biopharmaceutical research projects of talented young scientists in the United States. A total of 16 recipients were selected and more than $1 million was awarded.
the National Institutes of Health has renewed a Center of Biomedical Research Excellence (COBRE) grant at the University of Delaware. The COBRE research team is focused on discovery of new molecules that can be used to study and treat diseases such as breast cancer, renal cancer, Crohn’s disease, tuberculosis and Legionnaires disease.
New York University, Columbia University, and Takeda Pharmaceutical Company Limited (“Takeda”) have formed a collaborative research alliance to begin and advance gastroenterology research programs, with the goal of developing new therapies for patients with gastrointestinal and liver disorders.
The Huntsman Cancer Institute, College of Pharmacy and PIVOT Center have partnered to establish the University of Utah Therapeutic Accelerator Hub. The new Accelerator will provide resources and expertise to researchers to support the process of translating research discoveries into innovative clinical applications.
A machine learning model developed by a team of Lawrence Livermore National Laboratory (LLNL) scientists to aid in COVID-19 drug discovery efforts is a finalist for the Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research.
“There’s no place like home,” has its roots deep in the brain. Using fiber photometry, scientists are the first to show that home evokes a surge of dopamine in mice that mimics the response to a dose of cocaine. The study demonstrates how dopamine rises rapidly in mice moved from a simple recording chamber to their home cage, but less so when they return to a cage not quite like the one they knew.
Using 3-D cell culture, researchers identify a promising drug lead against a bladder cancer subtype
Lawrence Livermore National Laboratory and its partners AMD, Supermicro and Cornelis Networks have installed a new high performance computing (HPC) cluster with memory and data storage capabilities optimized for data-intensive COVID-19 research and pandemic response.
Anyone with a smartphone can download the app ViDok, which lets users pick from a library of molecules that might bind to key proteins on the SARS-CoV-2 virus, which causes COVID-19, and then can tweak the molecules to try to find a better fit.
The drug discovery program is focused on the assessment of hundreds of drug candidates in the CDI labs, to find the most promising potential therapies.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu